Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC response, and simultaneous generation of patient-derived xenografts (PDXs) may accelerate drug development. However, the feasibility of this approach is unknown. Methods: We conducted a prospective study of 140 breast cancer patients treated with NAC and performed tumor and germline sequencing and generated patient-derived xenografts (PDXs) using core needle biopsies. Chemotherapy response was assessed at surgery. Results: Recurrent "targetable" alterations were not enriched in patients without pathologic complete response (pCR); however, upregulation of steroid receptor signaling and lower pCR rates (16.7%, 1/6) were observed in triple-negative breast cancer (TNBC) patients with luminal androgen receptor (LAR) vs basal subtypes (60.0%, 21/35). Within TNBC, TP53 mutation frequency (75.6%, 31/41) did not differ comparing basal (74.3%, 26/35) and LAR (83.3%, 5/6); however, TP53 stop-gain mutations were more common in basal (22.9%, 8/35) vs LAR (0.0%, 0/6), which was confirmed in The Cancer Genome Atlas and British Columbia data sets. In luminal B tumors, Ki-67 responses were observed in tumors that harbored mutations conferring endocrine resistance ( p53, AKT, and IKBKE ). PDX take rate (27.4%, 31/113) varied according to tumor subtype, and in a patient with progression on NAC, sequencing data informed drug selection (olaparib) with in vivo antitumor activity observed in the primary and resistant (postchemotherapy) PDXs. Conclusions: In this study, we demonstrate the feasibility of tumor sequencing and PDX generation in the NAC setting. "Targetable" alterations were not enriched in chemotherapy-resistant tumors; however, prioritization of drug testing based on sequence data may accelerate drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 2×
“66% (31/41), which compared similarly with the TCGA (4) and British Columbia (BC) cohorts (Supplementary Table 22, available online) (17) and did not differ comparing basal (74.”
BackgroundResultGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · cited 2×
“Patient-derived xenografts (PDXs) are increasingly used as a tool to study the impact of new drugs (7,8).”
Cited by
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform
Lanz, H. L., Saleh, A., Kramer, B., Cairns, J., Ng, C. P., Yu, J., Trietsch, S. J., Hankemeier, T., Joore, J., Vulto, P., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3709-3 · Cited by 135
Self-citationChemotherapy-induced senescent cancer cells engulf other cells to enhance their survival
Tonnessen-Murray, C. A., Frey, W. D., Rao, S. G., Shahbandi, A., Ungerleider, N. A., Olayiwola, J. O., Murray, L. B., Vinson, B. T., Chrisey, D. B., Lord, C. J., et al. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201904051 · Cited by 127
Zhuang, Y., Grainger, J. M., Vedell, P. T., Yu, J., Moyer, A. M., Gao, H., Fan, X.-Y., Qin, S., Liu, D., Kalari, K. R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00285-x · Cited by 11
Self-citation
Metadata
- Authors
- Goetz, M. P., Kalari, K. R., Suman, V. J., Moyer, A. M., Yu, J., Visscher, D. W., Dockter, T. J., Vedell, P. T., Sinnwell, J. P., Tang, X., Thompson, K. J., Barman, P., Mahoney, D. W., Carlson, E., Hart, S. N., Yin, P., Qin, B., Felten, S. J., McLaughlin, S. A., Moreno-Aspitia, A., Copland, J. A., Northfelt, D. W., Gray, R. J., Hunt, K., Conners, A., Sicotte, H., Eckel-Passow, J. E., Kocher, J.-P., Ingle, J. N., Ellingson, M. S., McDonough, M., Wieben, E. D., Weinshilboum, R., Wang, L., & Boughey, J. C.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-09
- Volume
- 109
- Issue
- 7
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2593920943
- Cited by
- 80
- References
- 4
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. https://app.cochat.ai/papers/10.1093/jnci/djw306
- The paper
- Goetz, M. P., Kalari, K. R., Suman, V. J., Moyer, A. M., Yu, J., Visscher, D. W., Dockter, T. J., Vedell, P. T., Sinnwell, J. P., Tang, X., Thompson, K. J., Barman, P., Mahoney, D. W., Carlson, E., Hart, S. N., Yin, P., Qin, B., Felten, S. J., McLaughlin, S. A., . . . Boughey, J. C. (2017). Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djw306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.